Kirill Karlin, MD
@kirillkarlin
Hematopathology fellow @BWHPath, Pathology resident @BIDMCPath @HarvardMed
ID: 287424556
http://www.karlin.xyz 24-04-2011 23:52:58
135 Tweet
414 Takipçi
1,1K Takip Edilen
🔥 Just out on Nature - ctDNA guiding adjuvant IO in urothelial cancer With IO reaching the (neo)adjuvant setting in multiple oncological diseases (including #TNBC), optimally identifying responders is a main research priority Congrats Tom Powles & colleagues!!!
Super excited to start Biodraft_ with Liang Chang, a biotech substack, where we will be posting monthly biotech deep-dives. Check out Liang Chang fantastic overview article on gene editing and gene therapy landscape on Biodraft_ biodraft.substack.com/p/therapeutics…
Introducing our new blog article on Biodraft_! In this article, Kirill Karlin, MD and myself looked into >30 platform biotech companies and share what we learned about their phenotypes, business models, trajectories, and beyond. Hope you will enjoy it! biodraft.substack.com/p/deep-dive-in…
Biotech corporate development workflow from biodraft.substack.com/p/deep-dive-in… from Liang Chang and Kirill Karlin, MD
Our new deep dive into 30+ platform biotech companies. Liang Chang and I looked closer into their phenotypes, business models, and destinations. biodraft.substack.com/p/deep-dive-in….
It was super fun to provide (together with Tamara Prieto) additional context/thoughts Nature News & Views to recent amazing paper about non-genetic determinants of malignant clonal fitness. Congrats to Mark Dawson Dane Vassiliadis @KatieAFennell and the entire team! nature.com/articles/d4158…
So that was impressive Siddhartha Jaiswal Jennifer Trowbridge : Dr Hind Bouzid presented several lines of evidence that CHIP reduces Alzheimer risk (multiple cohorts, clonal cells in brain indistinguishable from microglia). Hypothesis #CHIP cells supplement loss of microglia during aging.
New report in @nature from Alex Cagan and coworkers measures an inverse correlation between somatic mutation rate and lifespan among 15 mammalian species. Inspires brainstorming about correcting cellular mutations as a potential way to protect lifespan… 🤔
Our new blog article on Biodraft_! Why having a blockbuster drug is both a blessing and a curse? Kirill Karlin, MD and I looked into ~10 commercial-stage biotech companies to find out what happened after their first blockbuster. Tell us what you think! biodraft.substack.com/p/the-blockbus…
Great Substack highlighting key trends in #biotech by Liang Chang and Kirill Karlin, MD. Nicely done! biodraft.substack.com/?r=1m5xy3&utm_…
The first study on the prevalence of smoldering myeloma just published in Nature Medicine ! Full link: rdcu.be/c4026 We found the prevalence of SMM to be 0.5% in people >40 years
Awesome Ph.D. defense by Liang Chang from The Sellers Lab!! 🎉 Really cool learning how to better derisk new targets for targeted cancer treatments. I could see pharma using this framework to prioritize early pipelines and better understand emerging competitive landscapes.